Keno Gutierrez

General Partner

2021

Chairman of the Board

2022

First-in-class small inhibitors for treatment of a range of neurodegenerative diseases by safely counteracting glutamate excitotoxicity.

Board Member

2022

Board Member

2022

Fibrocor utilizes its proprietary drug discovery engine to develop new medicines for individuals with fibrotic diseases.

Board Member

2021

Observer, former Chairman and Board Member

2022

T-reg targeted therapies for long-lasting autoimmune disease control

Managing Director and Vice President

2021 - 2021

Strategic corporate venture capital arm of Merck, with €300m of investable capital. I invest in innovation, being jointly responsible for all biotechnology investments (biotherapeutics and life sciences tools and consumables). I act as the Life Sciences Interface with Merck.

Executive Investment Director

2020 - 2021

Investment Director Healthcare

2017 - 2020

Board Observer

2021 - 2021

Riffyn’s pioneering cloud system, Riffyn Nexus, is a process data system that places R&D process flows at the center of heterogeneous and fragmented R&D environments, delivering 2X faster development cycles and 4X productivity gains to the world’s scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of traditional scientific data systems — delivering results that are always ready for machine learning.

Board Observer

2020 - 2021

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, making this technology accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX™ System.

Board Observer

2019 - 2021

Single cell genomics-based approaches to identify novel immuno-oncology targets